These findings provide preclinical proof of concept that KAT6A is a druggable cancer target, supporting the notion that a novel class of epigenetic drugs targeting KAT6A may be a practical and effective approach for ER+/HER2− breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.